Clinical Research Directory
Browse clinical research sites, groups, and studies.
The Role of Islet GLP-1 in the Pathogenesis of Prediabetes
Sponsor: Mayo Clinic
Summary
We recently demonstrated that blockade of Glucagon-Like Peptide-1's (GLP-1) receptor (GLP1R) results in changes in islet function without changes in circulating GLP-1. These effects are more pronounced in people with early type 2 diabetes (T2DM) in keeping with increased expression of PC-1/3 and GLP-1 that is observed in diabetic islets. However, its regulation is at present unknown. At present it is unknown if these abnormalities develop in prediabetes and whether they contribute to the phenotypes observed. In this experiment we will use blockade of GLP1R to probe the contribution of endogenous GLP-1 secretion to the regulation of fasting glucose and islet function in prediabetes.
Key Details
Gender
All
Age Range
25 Years - 70 Years
Study Type
INTERVENTIONAL
Enrollment
60
Start Date
2025-11-01
Completion Date
2028-03-31
Last Updated
2025-12-15
Healthy Volunteers
Yes
Conditions
Interventions
Exendin 9-39
Exendin 9-39 is a competitive antagonist of the GLP-1 receptor
Saline
Saline
Locations (1)
Mayo Clinic in Rochester
Rochester, Minnesota, United States